During the Spring 2026 semester, Ne\u015fe Devenot contributed expertise to journalistic investigations and informed popular media about the emerging psychedelic industry:<\/p>\n\n\n\n
On February 26, Devenot was quoted in \u201cPsychedelika: Wohin treibt die Renaissance von LSD & Co.<\/u><\/a>?\u201d by Jonas Staehelin in WOZ Die Wochenzeitung<\/em>, an independent national newspaper in German-speaking Switzerland. In an article examining how right-wing figures in the United States have increasingly championed psychedelic research, Devenot warned that billionaire control over the context and interpretation of psychedelic medicine threatens to transform these substances into instruments of social control. Devenot emphasized that their emancipatory or oppressive potential depends fundamentally on whether they serve elite class interests or collective needs.<\/p>\n\n\n\n On April 2, Law & Order: SVU<\/u><\/em>\u2019s episode \u201cVivid\u201d<\/u><\/a> (Season 27, Episode 16) centered on an investigation into a psychedelic therapy patient\u2019s memory of assault during a clinical trial. The episode drew on real-world issues that were documented by Devenot and their nonprofit Psymposia, including therapist misconduct and undisclosed pseudoscientific practices in Lykos Therapeutics\u2019 MDMA-assisted therapy trials alongside institutional efforts to protect the emerging psychedelic industry from scrutiny.<\/p>\n\n\n\n On April 14, Devenot was quoted in \u201cThe Double Visions of Ketamine Therapy<\/u><\/a>\u201d by David Rosenbloom in The New Journal, Yale University\u2019s student magazine. The investigative feature examined competing approaches to ketamine therapy in New Haven, contrasting the pharmacological emphasis of medical clinics with \u201cholistic\u201d clinics that treat the ketamine session as a psychotherapeutic encounter. Devenot warned that the latter model creates risks for coercive dynamics, noting that psychedelic therapy attracts desperate, vulnerable patients alongside pseudoscientific practitioners in a context of pharmaceutically-enhanced suggestibility. Devenot emphasized that industry hype around psychedelics as \u201cthe future of mental health care\u201d masks these ethical risks, normalizing therapeutic practices that lack adequate safeguards.<\/p>\n\n\n\n